Bharat Biotech to Tackle Global Cholera Crisis with New Oral Vaccine

India's Vaccine Giant Prepares to Launch Hillchol Amidst Worsening Global Shortage

India's Bharat Biotech is stepping up to address the escalating global cholera crisis with the introduction of its new oral cholera vaccine, Hillchol. Following a successful late-stage trial, the company announced plans to produce up to 200 million doses annually, aiming to mitigate the severe shortage of cholera vaccines as outbreaks intensify worldwide.

Hillchol, which recently received approval from India’s drug regulator, is poised to make a significant impact on global health. Bharat Biotech is now seeking pre-qualification from the World Health Organization (WHO), a critical step in supplying the vaccine to major international buyers, including UNICEF. With this move, Bharat Biotech will enter a competitive market currently dominated by South Korea's EuBiologics Co, the only other WHO-approved cholera vaccine producer.

Bharat Biotech has made it clear that its primary focus is on Africa, where cholera outbreaks have been particularly devastating. The company is open to collaborating with African nations by supplying the drug substance for local manufacturing. Production will commence at Bharat Biotech’s Hyderabad facility, which has an initial capacity of 45 million doses per year. The company is also awaiting approval for an additional facility that will enable them to scale up production to the full 200 million doses.

Approximately $100 million has been invested in the facilities dedicated to Hillchol’s production, though Bharat Biotech has kept specific investment details under wraps. The vaccine’s late-stage trial involved around 3,600 participants in India and demonstrated safety and efficacy comparable to existing oral cholera vaccines.

As the global cholera situation worsens, with WHO reporting over 249,000 cases and 2,137 deaths in the first half of the year alone, the demand for vaccines has surged. With a current annual shortage of 40 million doses, Bharat Biotech’s Hillchol could be a crucial lifeline in the fight against this deadly disease, offering protection to those most at risk, including children as young as one.